Online inquiry

IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2583MR)

This product GTTS-WQ2583MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MPL gene. The antibody can be applied in Chronic immune (idiopathic) thrombocytopenic purpurea (ITP) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005373.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4352
UniProt ID P40238
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2583MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5657MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ8936MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ13408MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ4262MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ7520MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ1050MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ2264MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALX-0171
GTTS-WQ14711MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SEG101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW